Cronos Group Inc. (CRON) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cronos Group Inc. (CRON) opera en el sector Healthcare, cotizado por última vez a $2.50 con una capitalización de mercado de 962M. La acción obtiene una puntuación de 62/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 8 feb 2026Cronos Group Inc. (CRON) Resumen de Asistencia Médica y Tuberías
Cronos Group Inc. is a global cannabinoid innovator with a diverse portfolio of wellness and adult-use cannabis brands, leveraging strategic partnerships and international expansion to capitalize on the burgeoning cannabis market and drive long-term growth, boasting a 27.2% profit margin.
Tesis de Inversión
Cronos Group presents a notable research candidate within the rapidly expanding cannabis industry. The company's diversified brand portfolio, including Lord Jones and Spinach, caters to both the wellness and adult-use markets, providing multiple revenue streams. With a gross margin of 42.0% and a profit margin of 27.2%, Cronos demonstrates strong profitability potential. Key value drivers include the expansion of its product offerings, strategic partnerships, and penetration into new international markets. The company's focus on research and development positions it to capitalize on evolving consumer preferences and regulatory changes. Investors may want to evaluate CRON for long-term growth, driven by the legalization trends and increasing acceptance of cannabis globally.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $1.01B reflects investor confidence in Cronos Group's growth potential within the cannabis industry.
- P/E ratio of 28.06 indicates that investors are willing to pay a premium for Cronos Group's earnings, suggesting strong growth expectations.
- Profit Margin of 27.2% demonstrates Cronos Group's ability to generate substantial profits from its revenue.
- Gross Margin of 42.0% highlights Cronos Group's efficient cost management and pricing strategies.
- Beta of 1.18 suggests that Cronos Group's stock price is more volatile than the overall market, which may appeal to risk-tolerant investors seeking higher returns.
Competidores y Pares
Fortalezas
- Established brands (Lord Jones, Spinach).
- Diversified product portfolio.
- International presence.
- Strong profit margin (27.2%).
Debilidades
- Dependence on regulatory approvals.
- Intense competition in the cannabis industry.
- Limited brand awareness compared to larger competitors.
- Fluctuations in cannabis prices.
Catalizadores
- Upcoming: Potential regulatory changes in key markets, such as the United States and Europe, could create new opportunities for Cronos Group to expand its operations and increase sales.
- Ongoing: Continued expansion of the adult-use cannabis market in Canada and other countries is expected to drive revenue growth for Cronos Group.
- Ongoing: Development and launch of new and innovative cannabis products, such as cannabis-infused beverages and edibles, could attract new customers and increase market share.
- Ongoing: Strategic partnerships with established companies in related industries could provide Cronos Group with access to new markets and distribution channels.
Riesgos
- Potential: Regulatory uncertainty and changes in cannabis laws could negatively impact Cronos Group's operations and financial performance.
- Potential: Intense competition in the cannabis industry could put pressure on prices and margins.
- Ongoing: Negative public perception of cannabis could limit demand and hinder growth.
- Ongoing: Fluctuations in cannabis prices could impact Cronos Group's profitability.
- Potential: Dependence on key suppliers and distributors could disrupt the supply chain and impact sales.
Oportunidades de crecimiento
- Expansion of Product Portfolio: Cronos Group can drive growth by expanding its product portfolio to include new and innovative cannabis-derived products. This includes developing new formulations, delivery methods, and product categories to cater to evolving consumer preferences. The market for cannabis-infused beverages and edibles is projected to grow significantly, presenting a substantial opportunity for Cronos to capture market share. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with established companies in related industries, such as consumer packaged goods and pharmaceuticals, can provide Cronos Group with access to new markets, distribution channels, and technological expertise. Collaborating with beverage companies to develop cannabis-infused drinks or partnering with pharmaceutical companies to research and develop cannabis-based medicines could accelerate growth. Timeline: Ongoing.
- International Expansion: Expanding into new international markets, particularly in Europe and Latin America, presents a significant growth opportunity for Cronos Group. As more countries legalize cannabis for medical and adult-use purposes, Cronos can leverage its existing infrastructure and expertise to establish a presence in these emerging markets. Germany and other European countries represent attractive markets with high growth potential. Timeline: Ongoing.
- Research and Development: Investing in research and development to develop new and improved cannabis strains, cultivation techniques, and extraction methods can provide Cronos Group with a competitive advantage. Developing proprietary technologies and intellectual property can differentiate Cronos from its competitors and create barriers to entry. Focus on developing strains with specific cannabinoid profiles and therapeutic benefits. Timeline: Ongoing.
- E-commerce and Direct-to-Consumer Sales: Enhancing its e-commerce platform and expanding its direct-to-consumer sales channels can enable Cronos Group to reach a wider audience and increase sales. Investing in digital marketing and customer relationship management can improve customer engagement and drive repeat purchases. Focus on personalized product recommendations and targeted advertising to increase conversion rates. Timeline: Ongoing.
Oportunidades
- Expansion into new international markets.
- Development of new and innovative cannabis products.
- Strategic partnerships with established companies.
- Increasing legalization of cannabis globally.
Amenazas
- Changing regulations and policies.
- Increased competition from new entrants.
- Fluctuations in cannabis prices.
- Negative public perception of cannabis.
Ventajas competitivas
- Brand recognition through established brands like Lord Jones and Spinach.
- Strategic partnerships with established companies.
- Proprietary cultivation and extraction technologies.
- International distribution network.
Acerca de CRON
Cronos Group Inc., founded in 2012 and headquartered in Toronto, Canada, operates as a cannabinoid company, engaging in the manufacturing, marketing, and distribution of hemp-derived supplements and cannabis products. The company's initial focus was on cultivating and distributing cannabis in Canada's emerging medical market. Over time, Cronos has expanded its product offerings and geographic reach, establishing a presence in both the medical and adult-use markets. Cronos sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. Its brands include Lord Jones and Happy Dance, which offer hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels in the United States. The company also exports dried cannabis and cannabis oils to international markets such as Germany, Israel, and Australia. Cronos Group has a market capitalization of $1.01 billion and employs 459 people.
Qué hacen
- Cultivates and manufactures cannabis and cannabis-derived products.
- Markets and distributes hemp-derived supplements and cosmetic products.
- Sells dried cannabis, pre-rolls, edibles, and concentrates.
- Operates a wellness platform under the PEACE NATURALS brand.
- Manages adult-use brands, including Spinach.
- Exports dried cannabis and cannabis oils to international markets.
- Sells through wholesale and direct-to-client channels.
Modelo de Negocio
- Cultivation and production of cannabis and hemp.
- Manufacturing of cannabis-derived products, including edibles and concentrates.
- Distribution through wholesale channels to retailers.
- Direct-to-consumer sales through e-commerce platforms.
Contexto de la Industria
Cronos Group operates within the rapidly evolving cannabis industry, which is experiencing significant growth due to increasing legalization and changing consumer attitudes. The market is characterized by intense competition, with numerous players vying for market share. Cronos differentiates itself through its diversified brand portfolio, strategic partnerships, and international expansion efforts. The industry is subject to evolving regulations and shifting consumer preferences, requiring companies to adapt and innovate to remain competitive. As of 2026, the global cannabis market is projected to reach significant value, presenting substantial growth opportunities for companies like Cronos Group.
Clientes Clave
- Adult-use cannabis consumers.
- Medical cannabis patients.
- Retailers and distributors.
- E-commerce shoppers seeking hemp-derived supplements and cosmetics.
Finanzas
Gráfico e información
Precio de la acción de Cronos Group Inc. (CRON): $2.50 (+0.01, +0.40%)
Últimas noticias
-
The Major Long-Term Risk Facing Altria Stock in 2026
Motley Fool · 31 mar 2026
-
'White House Schedules Meeting On Cannabis Products Enforcement Policy For Next Week'- Marijuana Moment
benzinga · 26 mar 2026
-
'Marijuana Businesses Could List On US Stock Exchanges Like Nasdaq And NYSE Under New Bipartisan Congressional Bill' - Marijuana Moment
benzinga · 19 mar 2026
-
'Medicare CBD Pilot Will Allow Some THC in Products'- Cannabis Wire
benzinga · 19 mar 2026
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CRON.
Objetivos de Precios
Objetivo de consenso: $2.29
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CRON en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Últimas Noticias
The Major Long-Term Risk Facing Altria Stock in 2026
'White House Schedules Meeting On Cannabis Products Enforcement Policy For Next Week'- Marijuana Moment
'Marijuana Businesses Could List On US Stock Exchanges Like Nasdaq And NYSE Under New Bipartisan Congressional Bill' - Marijuana Moment
'Medicare CBD Pilot Will Allow Some THC in Products'- Cannabis Wire
CRON Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar CRON?
Cronos Group Inc. (CRON) actualmente tiene una puntuación IA de 62/100, indicando puntuación moderada. Los analistas apuntan a $2.29 (-8% desde $2.50). Fortaleza clave: Established brands (Lord Jones, Spinach).. Riesgo principal a monitorear: Potential: Regulatory uncertainty and changes in cannabis laws could negatively impact Cronos Group's operations and financial performance.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CRON?
CRON actualmente puntúa 62/100 (Grado B) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CRON?
Los precios de CRON se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CRON?
Los analistas han establecido un precio objetivo de consenso de $2.29 para CRON, representando un potencial bajista del 8% desde el precio actual de $2.50. La cobertura incluye calificaciones de compra, mantener y venta, estimaciones de ganancias y recientes mejoras o rebajas. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CRON?
Las categorías de riesgo para CRON incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory uncertainty and changes in cannabis laws could negatively impact Cronos Group's operations and financial performance.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CRON?
La relación P/E para CRON compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CRON sobrevalorada o infravalorada?
Determinar si Cronos Group Inc. (CRON) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Objetivo de analistas $2.29 (-8% desde el precio actual). Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CRON?
Cronos Group Inc. (CRON) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- The cannabis industry is rapidly evolving, and future performance is uncertain.